Clinical trials: Histological Response
Hepatocellular Carcinoma
Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the 7th most common cancer worldwide but is the 4th deadliest, because diagnosis tend to be late and current systemic therapies are poorly efficacious.
- Trial name
- EMPHASIS (NCT05516628)
- Testing
- Surgical Resection, Adjuvant Atezolizumab-Bevacizumab Therapy
- Where
- 6 sites in Singapore
- Volunteers
- 30 people
- Sponsor
- National Cancer Centre, Singapore
Colorectal Cancer, Esophageal Cancer
Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal Cancer
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00628368
- Testing
- Gene expression analysis
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Cutaneous T-cell Lymphoma, Sezary Syndrome
In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL)
This is an in vitro evaluation of cutaneous T-cell lymphoma using patients' blood and tissue to evaluate immune responses related to identified tumor populations and dendritic/CD 8 cells.
- Conditions
- Cutaneous T-cell Lymphoma, Sezary Syndrome, Mycosis Fungoides
- Trial name
- NCT00177190
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Pittsburgh
Head and Neck Cancer
3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) and fludeoxyglucose F 18 (FDG) PET scans, may help doctors predict a patient's response to treatment and help plan the best treatment.
- Trial name
- NCT00757549
- Testing
- cetuximab, cisplatin, TdT-mediated dUTP nick end labeling assay
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Hodgkin Lymphoma
Circulating Tumor DNA Genotyping for Biological Monitoring of Patients Treated in the FIL-Rouge Clinical Trial
Prospective, multicenter, non-interventional, biological study ancillary to FIL-Rouge clinical trial (NCT03159897) enrolling patients affected by Advanced-stage Hodgkin Lymphoma, ABVD-based upfront treatment in 19 centers in…
- Trial name
- FIL-RougeBIO (NCT05066555)
- Where
- 13 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Carcinoid Syndrome, Carcinoid
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and exploratory dose response of paltusotine treatment in subjects with carcinoid syndrome.
- Conditions
- Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum
- Trial name
- NCT05361668
- Testing
- Randomized: 40 mg Paltusotine, Randomized: 80 mg Paltusotine
- Where
- 35 sites in United States, Argentina and 5 more
- Volunteers
- 36 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Multiple Myeloma
UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib
The purpose of this study is to evaluate the overall response rate of Trametinib when administered orally to patients with relapsed or refractory multiple myeloma
- Trial name
- NCT02140840
- Testing
- Trametinib
- Where
- United States
- Sponsor
- University of Arkansas
HNSCC, OSCC
Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma
To investigate the neoadjuvant chemoimmunotherapy regimen of Ivonescimab combined with chemotherapy (Paclitaxel plus Cisplatin/Carboplatin) for the treatment of locally advanced resectable oral squamous cell carcinoma and…
- Conditions
- HNSCC, OSCC, OPSCC, Ivonescimab
- Trial name
- NCT07686575
- Testing
- Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Zhujiang Hospital
Carcinoma, Small Cell
Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient
Belotecan (Camtobell, CKD-602, Chong Kun Dang Pharm., Korea) is a new camptothecin derivative, that exhibits anticancer effects by inhibiting topoisomerase I.
- Trial name
- COMBAT (NCT00826644)
- Testing
- Belotecan, Etoposide, Cisplatin
- Where
- South Korea
- Volunteers
- 147 people
- Sponsor
- Chonnam National University Hospital
Carcinoma, Hepatocellular
DCE-MRI for Assessment of Response to TACE of HCC
This study is conducted to evaluate dynamic contrast-enhanced MRI to quantify the efficacy of trans-arterial chemoembolization by comparing imaging results before and after treatment for at least one hepatic tumor and to look at…
- Trial name
- DCE-MRI (NCT02878109)
- Testing
- Post-treatment phase group, Pre-treatment phase group
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Hepatocellular Carcinoma (HCC)
Predicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver)
CT imaging data and MR imaging data from liver cancer (hepatocellular carcinoma) patients prior to the initiation of immunotherapy (and possibly also after treatment) will be collected.
- Trial name
- NCT07059936
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Bloodstream Infection, Acute Myeloid Leukemia
Efficacy of Antibiotic Short Course for Bloodstream Infections in Acute Myeloid Leukemia Patients With Febrile Neutropenia
There is no specific recommendation about antimicrobial treatment length for documented infections in chemotherapy induced febrile neutropenia.
- Conditions
- Bloodstream Infection, Acute Myeloid Leukemia, Febrile Neutropenia
- Trial name
- NCT04910698
- Testing
- Antibiotic
- Where
- France
- Volunteers
- 104 people
- Sponsor
- Poitiers University Hospital
Neuroendocrine Tumor, Malignant, Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting
Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors
This study is designed to identify the best tolerated doses of [131]Iodine-MIBG and [90]Yttrium-DOTATOC when co-administered to treat midgut neuroendocrine tumors.
- Trial name
- NCT03044977
- Testing
- 90Y-DOTA-3-Tyr-Octreotide, 131I-MIBG
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- David Bushnell
Myeloma Multiple
Immune Fitness in Older Patients With Relapsed and Refractory Multiple Myeloma
Relapsed/refractory multiple myeloma (RRMM) predominantly affects older adults, who exhibit marked heterogeneity in treatment outcomes despite receiving the same therapies.
- Trial name
- PRIME (NCT07674498)
- Testing
- immunophenotyping of lymphocyte
- Where
- 3 sites in Belgium
- Volunteers
- 31 people
- Sponsor
- Jules Bordet Institute
Ganglioneuroblastoma, Localized Resectable Neuroblastoma
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma. Sometimes a tumor may not need treatment until it progresses.
- Conditions
- Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Neuroblastoma
- Trial name
- NCT02176967
- Testing
- Biopsy Procedure, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 222 sites in United States, Australia and 4 more
- Volunteers
- 391 people
- Sponsor
- Children's Oncology Group
Hematological Malignancies
Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies
This study is a prospective, non-randomized feasibility study of drug response profiling (DRP) in pediatric blood cancers. Primary cancer cells are isolated from patients and screened ex vivo at single-cell resolution using…
- Trial name
- DRP_ZH (NCT06550102)
- Where
- Switzerland
- Volunteers
- 1,000 people
- Sponsor
- University Children's Hospital, Zurich
B Cell Lymphoma, Multiple Mieloma
Immunomonitoring and Predictive Biomarkers After CAR-T Cell Therapy in B-Cell Lymphoma and Multiple Myeloma
CARBIOM is a single-centre, non-randomized interventional study involving additional biological sampling with minimal risks and constraints.
- Trial name
- CARBIOM (NCT07852377)
- Testing
- Biological sample collection and immunomonitoring
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Centre Henri Becquerel
Melanoma
Influence of a High-fiber Diet on the Microbiota and the Response to Immunotherapy in Patients Treated for Melanoma.
The underlying hypothesis of the study is that melanoma patients treated with immunotherapy, whether in an adjuvant or curative setting, who consume more fiber would respond better to immunotherapy: either no recurrence in the…
- Trial name
- FIBIOME (NCT07437300)
- Volunteers
- 60 people
- Sponsor
- University Hospital, Grenoble
Non-Small Cell Lung Cancer, Melanoma (Skin Cancer)
Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis
The objective of this prospective multicenter study is to evaluate whether the analysis of immunological biomarkers present in circulating extracellular vesicles is associated with the response to anti-PD-1/PD-L1 treatments in…
- Trial name
- EVpredict (NCT07376512)
- Where
- 5 sites in France
- Volunteers
- 378 people
- Sponsor
- Centre Georges Francois Leclerc
Multiple Myeloma
Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy
This is a randomized, 2-arm phase II, multi-center study to evaluate the overall response rate in newly diagnosed, transplant ineligible patients receiving 9 cycles induction therapy with either KTd or KRd followed by…
- Trial name
- NCT02891811
- Testing
- Carfilzomib, Thalidomide, Lenalidomide
- Where
- 21 sites in Austria, Germany
- Volunteers
- 124 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.